Key result
In patients undergoing mitral surgery, severe pulmonary hypertension was associated with 0.98% hospital mortality versus 0% for moderate pulmonary hypertension, with significant postoperative sPAP reductions.
Why the study?
Does mitral valve surgery improve pulmonary arterial systolic pressure and survival in patients with rheumatic mitral disease and pulmonary hypertension?
Population
201 patients operated for mitral or mitro-tricuspid disease with pulmonary arterial hypertension
Comparison
Mitral or mitro-tricuspid valve surgery vs Moderate PAH (Group A) versus Severe PAH (Group B)
Design
Cohort
Follow-up
mean 61.73 months (range 30 to 108 months)
Authors
Loading...
May support mitral surgery in severe PH; leaves open need for randomized survival confirmation.
Observational (n=201)
No
Does mitral valve surgery improve pulmonary arterial systolic pressure and survival in patients with rheumatic mitral disease and pulmonary hypertension?
Absolute Event Rate: 0.98% vs 0%
Mitral valve surgery in patients with rheumatic heart disease and severe pulmonary hypertension leads to significant reductions in pulmonary pressures and excellent long-term survival, suggesting severe PAH should not be an absolute contraindication.
Bendjaballah et al. (2017) conducted an observational in Mitral or mitro-tricuspid disease with pulmonary arterial hypertension (n=201). Severe pulmonary hypertension (sPAP ≥ 60 mmHg) vs. Moderate pulmonary hypertension (40 ≤ sPAP < 60 mmHg) was evaluated on Global hospital mortality. In patients undergoing mitral surgery, severe pulmonary hypertension was associated with 0.98% hospital mortality versus 0% for moderate pulmonary hypertension, with significant postoperative sPAP reductions.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: